

Ref No. NLL/CS/2016-44

February 08, 2016

1. National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Unaudited Financial Results.

Ref: Compliance under Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sirs,

Pursuant to captioned Regulation, please find enclosed herewith a copy of the Unaudited Financial Results for the period ended on December 31, 2015, as approved by the Board of Directors in their meeting held on even date i.e. February 08, 2016. A copy of the Limited Review Report is also enclosed herewith for your record please.

Kindly acknowledge receipt of the same and oblige.

Thanking you,

Yours faithfully,
For NECTAR LIFESCIENCES LIMITED


Sunder Lal
Company Secretary

Encl. as above



NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab), Corporate Identification Number: L24232PB1995PLC016664
Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email : sunderal@neclife.com, Website : www.neclife.com

Part I - Statement of Unaudited Financial Results for the Quarter and Nine Months ended 31.12.2015 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended	Quarter ended	Quarter ended	9 Month ended	9 Month ended	Year ended
		31-12-15	30-09-15	31-12-14	31-12-15	31-12-14	31-03-15
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations						
	(a) Gross Sales	43,380.52	42,156.76	47,147.37	128,689.47	129,474.06	174,638.61
	Less : Excise Duty	3,653.14	2,490.18	2,735.69	8,526.83	7,531.02	10,349.72
	Net Sales	39,727.37	39,666.58	44,411.68	120,162.63	121,943.04	164,288.89
	(b) Other Operating Income	1.10	0.16	32.29	2.78	61.48	75.30
	Total Income from Operations (net)	39,728.47	39,666.74	44,443.97	120,165.41	122,004.52	164,364.19
2.	Expenses						
	(a) Cost of Materials consumed	25,999.48	25,583.76	29,783.10	78,052.57	79,893.36	112,990.38
	(b) Purchase of Stock in Trade	429.28	1,038.60	1,528.22	2,322.46	3,678.31	3,960.61
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	121.09	(160.23)	178.79	251.22	1,080.93	(2,817.56)
	(d) Employee benefits expense	1,794.10	1,716.88	1,501.69	5,197.84	4,352.20	6,270.67
	(e) Depreciation and amortisation expense	2,202.68	2,194.06	1,907.31	6,575.45	5,718.29	7,656.43
	(f) Other expenses	4,131.90	4,128.26	4,154.93	12,673.84	11,896.98	17,269.38
	Total Expenses	34,678.53	34,501.33	39,054.04	105,073.38	106,620.07	145,329.91
3.	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	5,049.94	5,165.41	5,389.93	15,092.03	15,384.45	19,034.28
4.	Other Income	171.89	127.02	221.72	425.62	718.26	1,999.88
5.	Profit before finance costs and exceptional items (3+4)	5,221.83	5,292.42	5,611.65	15,517.65	16,102.71	21,034.15
6.	Finance costs	3,035.96	3,082.20	3,482.54	8,851.40	9,871.13	12,558.79
7.	Profit after finance costs but before exceptional items (5-6)	2,185.86	2,210.23	2,129.11	6,666.24	6,231.58	8,475.37
8.	Exceptional items	-	-	-	-	-	-
9.	Profit from ordinary activities before tax (7+8)	2,185.86	2,210.23	2,129.11	6,666.24	6,231.58	8,475.37
10.	Tax Expense	445.78	477.80	440.58	1,452.38	1,276.22	1,848.98
11.	Net Profit from ordinary activities after tax (9-10)	1,740.08	1,732.43	1,688.53	5,213.86	4,955.36	6,626.39
12.	Extraordinary item (net of tax expense)	-	-	-	-	-	-
13.	Net Profit for the period (11-12)	1,740.08	1,732.43	1,688.53	5,213.86	4,955.36	6,626.39
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	-	-	93,552.29
16.i	Earnings per Share (EPS) (before extraordinary items)						
	a) Basic	0.78	0.77	0.75	2.32	2.21	2.95
	b) Diluted	0.78	0.77	0.75	2.32	2.21	2.95
16.ii	Earnings per Share (EPS) (after extraordinary items)						
	a) Basic	0.78	0.77	0.75	2.32	2.21	2.95
	b) Diluted	0.78	0.77	0.75	2.32	2.21	2.95

Part II Select Information for the Quarter and Nine month ended 31.12.2015

A		Particulars of shareholding					
1.	Public Shareholding						
	- Number of Shares	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	55,555,600	55,555,600	55,555,600	55,555,600	55,555,600	55,555,600
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.85	55.85	55.85	55.85	55.85	55.85
	- Percentage of Shares (as a % of the total share capital of the company)	24.77	24.77	24.77	24.77	24.77	24.77
	b) Non-encumbered						
	- Number of Shares	43,912,400	43,912,400	43,912,400	43,912,400	43,912,400	43,912,400
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.15	44.15	44.15	44.15	44.15	44.15
	- Percentage of Shares (as a % of the total share capital of the company)	19.58	19.58	19.58	19.58	19.58	19.58
B		Investor Complaints					
		3 Months ended 31.12.2015					
		Pending at the beginning of Quarter					
		Received During the Quarter					
		Disposed Off During the Quarter					
		Pending at the end of Quarter					

Notes:

- The above financial results were reviewed by Audit Committee on 06.02.16 and approved by the Board in its meeting held on even date i.e. 08.02.16 and further limited reviewed by the Statutory Auditors of the Company.
- The company is exclusively in the pharmaceutical business segment.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- The above financial results are on stand alone basis.
- These results are also available on the Company's website i.e. http://www.neclife.com/investor_relations.php and on the website of the Stock Exchanges at www.bseindia.com and www.nseindia.com.

Dated: 08.02.2016
Place: Chandigarh



By Order of the Board of Directors
of Nectar Lifesciences Limited
(Dinesh Dua)
Chief Executive Officer & Director



DATTA SINGLA & CO.
Chartered Accountants

SCO 2935-36, Level 1, Sector 22-C,
Chandigarh - 160 022 (INDIA)
Tele : +91-172-2707065, 5086551 / 52
Fax : +91-172-5019550

To Whomsoever It May Concern

Review Report to Board of Directors of Nectar Lifesciences Limited

We have reviewed the accompanying statement of unaudited financial results of Nectar Lifesciences Limited for the period ended December 31, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Datta Singla & Company
Chartered Accountants

Firm Regn. No. 006185N

CHARTERED
ACCOUNTANT
CHANDIGARH

(YOGESH MONGA)

PARTNER

M. No.: 099813

Place: Chandigarh

Date: 08.02.2016